Cost analysis of rapid diagnostics for drug-resistant tuberculosis

被引:10
|
作者
Groessl, Erik J. [1 ,2 ]
Ganiats, Theodore G. [1 ]
Hillery, Naomi [1 ]
Trollip, Andre [3 ]
Jackson, Roberta L. [4 ]
Catanzaro, Donald G. [5 ]
Rodwell, Timothy C. [4 ]
Garfein, Richard S. [4 ]
Rodrigues, Camilla [6 ]
Crudu, Valeriu [7 ]
Victor, Thomas C. [3 ]
Catanzaro, Antonino [4 ]
机构
[1] Univ Calif San Diego, Dept Family Med & Publ Hlth, 9500 Gilman Dr,0994, San Diego, CA 92103 USA
[2] VA San Diego Healthcare Syst, San Diego, CA 92161 USA
[3] Stellenbosch Univ, Dept Biomed Sci, Cape Town, South Africa
[4] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA
[5] Univ Arkansas, Little Rock, AR 72204 USA
[6] Hinduja Natl Hosp, Bombay, Maharashtra, India
[7] Inst Phthisiopneumol, Microbiol & Morphol Lab, Kishinev, Moldova
来源
BMC INFECTIOUS DISEASES | 2018年 / 18卷
关键词
Drug-resistant tuberculosis; Diagnosis; Cost-effectiveness; Time to result; MYCOBACTERIUM-TUBERCULOSIS; 2ND-LINE DRUGS; XPERT MTB/RIF; PREVENTION; ASSAY;
D O I
10.1186/s12879-018-3013-0
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Growth-based drug susceptibility testing (DST) is the reference standard for diagnosing drug-resistant tuberculosis (TB), but standard time to result (TTR) is typically >= 3 weeks. Rapid tests can reduce that TTR to days or hours, but accuracy may be lowered. In addition to the TTR and test accuracy, the cost of a diagnostic test may affect whether it is adopted in clinical settings. We examine the cost-effectiveness of rapid diagnostics for extremely drug-resistant TB (XDR-TB) in three different high-prevalence settings. Methods: 1128 patients with confirmed TB were enrolled at clinics in Mumbai, India; Chisinau, Moldova; and Port Elizabeth, South Africa. Patient sputum samples underwent DST for first and second line TB drugs using 2 growth-based (MGIT, MODS) and 2 molecular (Pyrosequencing [PSQ], line-probe assays [LPA]) assays. TTR was the primary measure of effectiveness. Sensitivity and specificity were also evaluated. The cost to perform each test at each site was recorded and included test-specific materials, personnel, and equipment costs. Incremental cost-effectiveness ratios were calculated in terms of $/day saved. Sensitivity analyses examine the impact of batch size, equipment, and personnel costs. Results: Our prior results indicated that the LPA and PSQ returned results in a little over 1 day. Mean cost per sample without equipment or overhead was $23, $28, $33, and $41 for the MODS, MGIT, PSQ, and LPA, respectively. For diagnosing XDR-TB, MODS was the most accurate, followed by PSQ, and LPA. MODS was quicker and less costly than MGIT. PSQ and LPA were considerably faster but cost more than MODS. Batch size and personnel costs were the main drivers of cost variation. Conclusions: Multiple factors must be weighed when selecting a test for diagnosis of XDR-TB. Rapid tests can greatly improve the time required to diagnose drug-resistant TB, potentially improving treatment success, and preventing the spread of XDR-TB. Faster time to result must be weighed against the potential for reduced accuracy, and increased costs.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Cost analysis of rapid diagnostics for drug-resistant tuberculosis
    Erik J. Groessl
    Theodore G. Ganiats
    Naomi Hillery
    Andre Trollip
    Roberta L. Jackson
    Donald G. Catanzaro
    Timothy C. Rodwell
    Richard S. Garfein
    Camilla Rodrigues
    Valeriu Crudu
    Thomas C. Victor
    Antonino Catanzaro
    [J]. BMC Infectious Diseases, 18
  • [2] Rapid detection of tuberculosis and drug-resistant tuberculosis
    Iseman, Michael D.
    Heifets, Leonid B.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (15): : 1606 - 1608
  • [3] Novel diagnostics and therapeutics for drug-resistant tuberculosis
    Toosky, Melody
    Javid, Babak
    [J]. BRITISH MEDICAL BULLETIN, 2014, 110 (01) : 129 - 140
  • [4] The future of molecular diagnostics for drug-resistant tuberculosis
    Heysell, Scott K.
    Houpt, Eric R.
    [J]. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2012, 12 (04) : 395 - 405
  • [5] Drug-resistant tuberculosis. Epidemiology, diagnostics and therapy
    Grobusch, M. P.
    Schaumburg, F.
    Altpeter, E.
    Belard, S.
    [J]. INTERNIST, 2016, 57 (02): : 126 - +
  • [6] Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis
    Pantoja, Andrea
    Fitzpatrick, Christopher
    Vassall, Anna
    Weyer, Karin
    Floyd, Katherine
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2013, 42 (03) : 708 - 720
  • [7] New and improved diagnostics for detection of drug-resistant pulmonary tuberculosis
    O'Grady, Justin
    Maeurer, Markus
    Mwaba, Peter
    Kapata, Nathan
    Bates, Matthew
    Hoelscher, Michael
    Zumla, Alimuddin
    [J]. CURRENT OPINION IN PULMONARY MEDICINE, 2011, 17 (03) : 134 - 141
  • [8] New developments in rapid diagnostics for drug resistant tuberculosis
    Nicol, M. P.
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2014, 21 : 18 - 18
  • [9] Rapid Molecular Assays for the Diagnosis of Drug-Resistant Tuberculosis
    Nandlal, Louansha
    Perumal, Rubeshan
    Naidoo, Kogieleum
    [J]. INFECTION AND DRUG RESISTANCE, 2022, 15 : 4971 - 4984
  • [10] Detecting Drug-Resistant Tuberculosis The Importance of Rapid Testing
    Hoek, Kim G. P.
    Van Rie, Annelies
    van Helden, Paul D.
    Warren, Robin M.
    Victor, Thomas C.
    [J]. MOLECULAR DIAGNOSIS & THERAPY, 2011, 15 (04) : 189 - 194